HCC UK is a multi-disciplinary organisation aiming to promote professional collaboration in research, education and clinical service development for primary liver cancers. We bring together leading oncologists, liver surgeons, hepatologists, basic scientists, radiologists, pathologists and specialist nurses to lead improvement in the quality of patient care. Its affiliation with BASL recognises the multi-disciplinary nature of collaboration in research and clinical practice.
BASL funded HCC-UK/NCRAS Partnership
Hepatocellular carcinoma rates are rapidly increasing in the UK in parallel with the increasing liver disease and the prognosis for patients is still poor. Hepatocellular carcinoma UK (HCC-UK) and the National Cancer Registration and Analysis Service (NCRAS) have formed a partnership to combine the expertise of HCC-UK with the extensive resource of the national cancer registry to conduct high quality research in to hepatocellular carcinoma
− Improving quality of liver cancer data
− Examine trends in HCC incidence, mortality and survival in the UK
− Identify the causes of the rising incidence of hepatocellular carcinoma
− Identify inequalities in incidence, survival and treatment
− Identify determinants of treatment allocation and survival
− Quantify NHS expenditure on HCC
Several groups are currently involved:
- Partnership lead
Anya Burton, HCC-UK and National Cancer Registration and Analysis Service, Public Health England
- Clinical leads
Graeme Alexander, UCL Institute for Liver and Digestive Health.
Aileen Marshall, Sheila Sherlock Liver Unit, Royal Free Hospital
- University of Leeds
Ian Rowe and Rob Driver
- Swansea University
Katherine Cullen, Rhys Pockett and Deb Fitzsimmons
- University of Liverpool
Vinay Kumar and Tim Cross
Please contact firstname.lastname@example.org for any enquiries about the work of the partnership, to see how we can help you improve your liver cancer data or if you are interested in discussing a potential research project using NCRAS data.
Liver-specific COSD item guidance
Liver-specific COSD item summary Download Liver-specific COSD item guidance v8.1.pdf
Liver-specific COSD item summary_Somerset Download Liver-specific COSD item guidance v8.1_Somerset.pdf
Guidance on how to complete the new liver-specific COSD items and when they are important to future liver cancer work. The Somerset version includes locations of each item in the Somerset Cancer Register.
Hepatocellular Carcinoma Staging Calculator - this tool is designed to aid calculation of the mandatory liver-specific COSD items BCLC stage, UKELD score and TNM stage, which are used to inform treatment decisions. Use of this calculator ensures standardised and accurate calculation of these items.
Macros must be enabled in order to complete the input required fields in yellow in the calculator worksheet; the output fields are in blue. Details of definitions, sources, developers and contacts are given in the remaining worksheets. Please contact email@example.com with enquires about the use of the calculator, if you require additional guidance or support in completing the new items of if you would like to know how this data will be used.
HCC UK Committee Elections 2021 - Expressions of Interest
The HCC UK Committee is currently seeking expressions of interest for a number of posts, see below. The group meet three to four times a year and all post holders will serve for three years and may be re-elected for one further term:
• Chair - will chair committee meetings
• Conference & education lead x 2
• Basic science lead
• Hepatology representative
• Oncology representative
• Surgery representative
• Radiology representative
Any BASL member who wishes to be affiliated to HCC UK can do so via the 'member area' of the BASL website or by emailing firstname.lastname@example.org .
Please send your nomination, clearly stating the position that your nomination is for to the BASL Secretariat at email@example.com before the deadline of 17:00 on Friday 13th August 2021.
Candidates wishing to be considered to join the HCC UK Committee should be a member of BASL and will require one BASL member to propose them and a second to confirm their suitability for the role in writing. (Proposing and seconding of candidates is by email.)
If more than one candidate is nominated the Secretariat will arrange for an election of BASL HCC UK members, in which all BASL members affiliated to HCC UK may vote. At this stage a personal statement will be requested from the candidates and the successful candidate will be elected by a simple majority of those members voting.
The HCC-UK Committee
Through its committee HCC-UK shall:
a) Maintain a suite of educational activities across basic research and clinical practice relating to primary liver cancer in the UK, acknowledging the multi-disciplinary nature of UK practice and including scientists, specialist, generalist and trainee clinicians.
b) Be a forum for sharing research initiatives, including the collection of material for national studies.
c) Build links with other health professionals in primary care, gastroenterology, radiology, surgery and pathology, including development of referral pathways that provide equity of access to surveillance, diagnosis and treatment for patients with primary liver cancer throughout the UK.
d) Develop guidelines to promote best practice.
e) Arrange an annual Business Meeting open to the full Group, to ensure that the formal organisational arrangements are adhered to.
The HCC-UK committee meetings take place three to four times a year.
|Chair||Aileen Marshall, Royal Free Hospital, London|
|Secretary||Tim Meyer, University College London|
|Conference & education co-leads||Helen Reeves, Newcastle University & Victoria Snowdon, Addenbrooke's Hospital, Cambridge|
|Basic science lead||Matthew Hoare, CRUK Cambridge Institute|
|Hepatology representative||Abid Suddle, King's College Hospital, London|
|Oncology representative||Richard Hubner, Christie NHS Foundation Trust|
|Surgery representative||Anya Adair, Royal Infirmary Edinburgh|
|Radiology representative||Teik Choon See, Addenbrookes Hospital, Cambridge|
|Pathology representative||Owen Cain, University Hospitals Birmingham|
|Nursing representative||Sarah Selemani, Kings College Hospital, London|